Countries Lead. We Stand Together. Systems Endure.

Global Health at this Moment

Despite strong progress toward the HIV 95-95-95 targets—reaching 88%-89%-95% in 2025—1.2 million people still acquired HIV, and disparities persist across populations and regions.

As shifts in global funding create uncertainty for HIV and TB programs, sustaining gains and closing gaps will require diversified financing, strategic partnerships, and country-led approaches.

The next phase of the HIV response will depend not only on innovation in prevention, treatment, and care, but also on building resilient, integrated health systems that countries can own, fund, and sustain through simplified service delivery models and locally driven innovation.

Partnership in Action

Jhpiego is an affiliate of Johns Hopkins University, with over 50 years of trusted partnerships in 140+ countries. Since 2001, Jhpiego has focused on ending AIDS and TB and reducing the burden of other infectious diseases, applying the best science to save lives. We bring innovation and access to the people and places that need them most – strengthening systems, driving partnerships and advancing equity to save and improve lives.

Our approach centers country governments as the drivers of sustainable change:

Navigate Transitions with Strategic Technical Assistance

- Rapid, adaptive support from locally-based, multidisciplinary teams who understand country contexts
- Implementation science that demonstrates what works—and what's cost-effective—to guide domestic investment priorities (e.g., oral and long-acting injectable pre-exposure prophylaxis [PrEP] and differentiated service delivery models for viral suppression)
- Data-driven approaches: from machine learning to predict treatment interruptions to e-dashboards for continuous quality improvement
- Leverage private sector and non-traditional partnerships (e.g., ePharmacy, traditional medicine providers and chemists) to expand reach sustainably

Co-Create Locally-Owned Solutions

- Work alongside national health teams to co-design and support implementation of solutions that fit country context
- Support governments to translate global evidence into country-adopted policies and practice
- Redesign how life-saving care is delivered, strenghen systems in which care is provided and strenghen a future ready workforce
- Elevate clients, health workers and communities as co-designers of their own health systems—using demand and design approaches that address the realities of each community.

On-the-Ground

- Jhpiego is implementing mentor mothers programs to provide same-day ART for pregnant and breastfeeding women and their HIV-exposed infants in Eswatini, Botswana, Mozambique, Nigeria and Sierra Leone. We also rolled out a mother-baby pair approach and community-based early infant diagnosis.
- In Nigeria, Jhpiego partnered with Palindrome Data to develop a locally customized HIV interruption in treatment (IIT) risk prediction algorithm. The model has been used to predict IIT for over 17,000 clients on ART, with a 94% prediction agreement rate with case managers. Over the study period, this approach led to a 4x reduction in IIT compared to standard care models.
- A leader in implementation science, Jhpiego has advanced access to oral and injectable PrEP and the vaginal ring. With WHO, Jhpiego developed a provider toolkit covering all recommended PrEP methods and is supporting government readiness and introduction for Lenacapavir (LEN) across Africa. In Eswatini, more than 1,100 clients initiated LEN between December 2025 and February 2026, while a PRO-funded study in Lesotho is informing LEN introduction among pregnant and breastfeeding women.

Reach and Impact

Through Jhpiego supported projects across multiple countries, between 2009 - FY26Q2:

24,920
babies were born HIV free

245,276
people initiated on PrEP

670,415
individuals diagnosed with HIV

21,278,319
people received HIV testing services, including 115,197 pregnant & lactating women in FY26 Q1-Q2

90%
(246,213/274,563) of individuals initiated & completed Tuberculosis Preventive Treatment (TPT)

686,227
people on lifesaving antiretroviral therapy (ART), 34,495 pregnant & lactating women on ART

97%
(366,293/378,953) viral load suppression (VLS)

Jhpiego's HIV/TB Portfolio, by Technical Focus



To learn more, visit
jhpiego.org